Polaris Peptides
Finnrick has tested 99 samples from Polaris Peptides across 9 products.
Take Action
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| GHK-Cu | 3 | 6 Aug 2025 | 25 Nov 2025 | |||||
| PT-141 | 6 | 6 Aug 2025 | 19 Aug 2025 | |||||
| Tirzepatide | 15 | 17 Dec 2024 | 19 Jan 2026 | |||||
| Mazdutide | 3 | 30 Apr 2025 | 6 May 2025 | |||||
| Survodutide | 5 | 25 Apr 2025 | 12 Aug 2025 | |||||
| BPC-157 | 12 | 17 Dec 2024 | 13 May 2026 | |||||
| CJC-1295 | 4 | 13 Feb 2025 | 21 Feb 2025 | |||||
| Semaglutide | 16 | 17 Dec 2024 | 12 Aug 2025 | |||||
| Retatrutide | 27 | 17 Dec 2024 | 13 May 2026 | |||||
The Polaris Peptides samples tested by Finnrick were either acquired by Finnrick directly, or submitted by the public.
Customer Reviews
These indicators of customer satisfaction are based on reports submitted by the public through the Finnrick testing program, and are not verified.
Based on 5 overall satisfaction reports
People who submitted test requests to Finnrick gave Polaris Peptides an average satisfaction rating of 4.4 out of 5 across 5 reports associated with samples received and tested by Finnrick. Customers rated ease of purchase (5.0/5), payment methods (5.0/5), delivery speed (5.0/5), and packaging quality (5.0/5) particularly highly.
Most recent Polaris Peptides tests
Samples are tested in commercial labs
tests
products
Scores
First
Last
| Quantity | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Test Score | Label | Batch | Tested | Difference | Purity | Endotoxins | Batch ID | Container | Tested At | Sent By |
| 13 May 2026 | BPC-157 | View | 5mg | 6.5mg | 5.83mg | -10.4% | 99.10% | n/a | POL-BPC5-2 | Black label / Silver crimp / Red cap | Lab E | Public | |
| 13 May 2026 | Retatrutide | View | 5mg | 5.6mg | 5.34mg | -4.6% | 99.90% | n/a | POL-R5-4 | Black label / Blue crimp / Clear cap | Lab E | Public | |
| 19 Jan 2026 | Tirzepatide | View | 30mg | (no batch claim) | 29mg | -3.3% | 99.35% | n/a | POL-T30-17 | No Label / Silver Crimp / Pink Cap | Lab E | Public | |
| 7 Jan 2026 | Retatrutide | View | 10mg | (no batch claim) | 10.4mg | +4.0% | 99.70% | n/a | (no batch ID) | No Label / Copper Crimp / Clear Cap | Lab G | Public | |
| 25 Nov 2025 | GHK-Cu | View | 2025-11-25mg | 68.4mg | 73.1mg | +6.9% | 99.93% | not detected | POL-GC50-4 | Black Label / Silver Crimp / Clear Pink Cap | Lab E | Finnrick | |
| 7 Nov 2025 | GHK-Cu | View | 50mg | 68.4mg | 69.35mg | +1.4% | 99.97% | n/a | POL-GC50-4 | Black Label / Silver Crimp / Clear Pink Cap | Lab A | Finnrick | |
| 9 Oct 2025 | Retatrutide | View | 5mg | (no batch claim) | 4.53mg | -9.4% | 99.53% | n/a | 520250728F | White Label / Silver Crimp / Black Cap | Lab E | Public | |
Corrections
- 15 Apr 2025: Retatrutide
- Lab B test 19 Feb 2025: updated quantity following the identification of a clerical error, value was erroneously listed as 6.25mg. Lab issued an updated test certificate on 7 Apr 2025.
About Polaris Peptides Test Results From Finnrick
Polaris Peptides is a peptide vendor with multiple products tracked in the independent testing dataset collected by Finnrick. This page compiles recent, batch-level test results across 9 products and 99 tests, including scores, test dates, batch IDs, and lab details. This enables you to compare quality over time, not just marketing claims.
Each tested sample receives a 0–10 score, with 10 being the best possible value. It is the total of three components: purity (0–4 points), quantity accuracy vs. the label or batch claim (0–4 points), and batch information quality (0–2 points).
When several test results are available for a product and vendor pair, you’ll also find a Finnrick Rating (A–E, where A is best and E is worst, X if an insufficient number of tests is available, or F in rare cases of documented and widespread fraud) and customer satisfaction reports with sub-scores that provide additional context. Use the table above to review purity, quantity accuracy, consistency between batches, and any notable outliers surfaced in Finnrick testing data.
Polaris Peptides Testing Activity & Score Summary
In the past 30 days, Finnrick has published 2 new test results for Polaris Peptides. The overall dataset includes 99 tested samples with an average score of 7.3/10 across all products.
Across 91 identity-tested samples, 100% were confirmed to contain the expected peptide (identity pass rate). Among those that passed, median purity was 99.8%. Approximately 98% of passing samples tested at or above 98% purity.
Here is a closer look at the most frequently tested products (top 3):
- Retatrutide (27 tests, 100% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 3.9 to 9.0 (average 7.4/10), suggesting significant batch-to-batch differences.
- Tirzepatide (15 tests, 100% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 6.5 to 10.0 (average 8.8/10), suggesting significant batch-to-batch differences.
- BPC-157 (12 tests, 100% identity pass, median purity 99.1%) — Test scores are highly variable, ranging from 4.5 to 7.9 (average 6.1/10), suggesting significant batch-to-batch differences.